Philips closes ATL acquisition
Philips parent Royal Philips Electronics of the Netherlands announced this month that the company has closed its acquisition of ATL Ultrasound of Bothell, WA. Philips acquired 94% of ATL shares Sept. 29, and the acquisition was completed Oct. 2 when ATL
Philips parent Royal Philips Electronics of the Netherlands announced this month that the company has closed its acquisition of ATL Ultrasound of Bothell, WA. Philips acquired 94% of ATL shares Sept. 29, and the acquisition was completed Oct. 2 when ATL merged with Philips Acquisition, and the remaining ATL shares were converted into the right for ATL to receive $50.50 per share in cash. The deal is estimated at roughly $800 million. ATL will become an affiliate of Philips Medical Systems.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
